Original Investigation
Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient

https://doi.org/10.1016/j.jacc.2015.09.073Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

Multiple randomized clinical trials comparing renal artery stent placement plus medical therapy with medical therapy alone have not shown any benefit of stent placement. However, debate continues whether patients with extreme pressure gradients, stenosis severity, or baseline blood pressure benefit from stent revascularization.

Objectives

The study sought to test the hypothesis that pressure gradients, stenosis severity, and/or baseline blood pressure affects outcomes after renal artery stent placement.

Methods

Using data from 947 patients with a history of hypertension or chronic kidney disease from the largest randomized trial of renal artery stent placement, the CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) study, we performed exploratory analyses to determine if subsets of patients experienced better outcomes after stent placement than the overall cohort. We examined baseline stenosis severity, systolic blood pressure, and translesion pressure gradient (peak systolic and mean) and performed interaction tests and Cox proportional hazards analyses for the occurrence of the primary endpoint through all follow-up, to examine the effect of these variables on outcomes by treatment group.

Results

There were no statistically significant differences in outcomes based on the examined variables nor were there any consistent nonsignificant trends.

Conclusions

Based on data from the CORAL randomized trial, there is no evidence of a significant treatment effect of the renal artery stent procedure compared with medical therapy alone based on stenosis severity, level of systolic blood pressure elevation, or according to the magnitude of the trans-stenotic pressure gradient. (Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions [CORAL]; NCT00081731)

Key Words

chronic kidney disease
hypertension
renal artery
stenosis
stent

Abbreviations and Acronyms

CORAL
Cardiovascular Outcomes in Renal Atherosclerotic Lesions
RAS
renal artery stenosis
SBP
systolic blood pressure

Cited by (0)

Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Numbers U01HL071556, U01HL072734, U01HL072735, U01HL072736, and U01HL072737. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drugs for this study were provided by AstraZeneca, device support was provided by Cordis Corporation, and supplemental financial support was granted by both Cordis Corporation and Pfizer Inc. Dr. Murphy owns equity in Anaxiom, Saphena Medical, Sentient Bioscience, and Summa Therapeutics; is a member of the data safety and monitoring board for Bard; and has a research contract with Novate and the Medicines Company. Dr. Cooper has received grant support for the CORAL trial from AstraZeneca, Pfizer, Cordis, and the National Heart, Lung, and Blood Institute of the National Institutes of Health. Dr. Matsumoto has received grant support from W. L. Gore, Medtronic, Insightec, and Cook; is a member of the data safety and monitoring board for Trivascular, Bolton Medical, and W. L. Gore; is a member of the scientific advisory board for Boston Scientific; is a member of the advisory board for Tenex Medical, BrightWater, and Siemens (uncompensated); and owns stock in Volcano Medical. Dr. Cutlip has received research support from Medtronic and Boston Scientific. Dr. Jamerson is a member of the data safety and monitoring board for Pfizer; and has received research support from Chantix. Dr. Tuttle has served as consultant for therapeutics for diabetic kidney disease for Eli Lilly and Company, Amgen, and Noxxon Pharma; and has received research support from Eli Lilly and Company. Dr. D’Agostino is a member of the data safety and monitoring board and executive committee for Merck, Johnson & Johnson, GlaxoSmithKline, and the Medicines Company. Dr. Massaro has served as a consultant for the Harvard Clinical Research Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.